Clinical Trial Update: Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating darbepoetin alfa for chemotherapy-induced anemia in patients with non-myeloid malignancies has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Cancer

Drugs mentioned

• ARANESP (DARBEPOETIN ALFA)

Snippet

Sponsor: Amgen | Conditions: Anemia, Cancer | Phase 2 | Status: COMPLETED